SDGR Schrodinger

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock option has an exercise price of $22.90 per share, equal to the closing price of the company’s common stock on March 14, 2025. The stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when the employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee’s completion of each additional month of service over the 36-month period following the first anniversary of the employment start date.

The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee’s completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date.

The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company’s 2021 Inducement Equity Incentive Plan.

About Schrödinger

Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit , follow us on , or visit our blog, .

EN
18/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Schrodinger

 PRESS RELEASE

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c...

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made ...

 PRESS RELEASE

Schrödinger Expands Board of Directors with Appointment of Bridget van...

NEW YORK--(BUSINESS WIRE)-- , Inc. (Nasdaq: SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: Bridget van Kralingen was appointed to Schrödinger’s Board of Directors in March 2025. (Photo: Business Wire) “Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board,” said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “Bridget’s leadership experience overseeing strategic initiatives at global ...

 PRESS RELEASE

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial...

NEW YORK--(BUSINESS WIRE)-- (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2024, and provided its financial outlook for 2025. “We are delighted with Schrödinger’s excellent financial performance in 2024. Software revenue growth exceeded our expectations, showing the resilience of our business through changing industry cycles and the impact of large contract renewals. Our drug discovery collaboration portfolio is expanding, driven by our new agreement with Novartis and expanded collaborations with Otsuka and Lilly, and we expect to re...

 PRESS RELEASE

Schrödinger to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E.T. Leerink Partners Global Biopharma Conference 2025: Fireside chat on Monday, March 10, 2025 at 3:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 18, 2025 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the even...

 PRESS RELEASE

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c...

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 17, 2025, the company granted restricted stock units (RSUs) with respect to 5,445 shares of the company’s common stock to five newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rul...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch